16 results on '"Hirohito, Takeuchi"'
Search Results
2. Irreversible electroporation of hepatocellular carcinoma: the role of ultrasonography
- Author
-
Katsutoshi Sugimoto, Masakazu Abe, Yu Yoshimasu, Hirohito Takeuchi, Yoshitaka Kasai, and Takao Itoi
- Subjects
irreversible electroporation ,hepatocellular carcinoma ,ultrasonography ,ablation ,Medical technology ,R855-855.5 - Abstract
Irreversible electroporation (IRE) is a novel form of soft tissue ablation therapy that uses high-current electrical pulses to induce the formation of pores in the cell membrane, leading to cell death. Although outcome data for the ablation of hepatocellular carcinoma (HCC) by IRE are limited, early results are encouraging and may suggest equivalency to the outcomes achieved by thermal ablation methods such as radiofrequency ablation (RFA) and microwave ablation (MWA). However, IRE can be a challenging and very time-consuming procedure compared to RFA and MWA. In this review article, we not only evaluate the efficacy and safety of IRE for the treatment of HCC, but also discuss imaging guidance, ablation monitoring, and endpoint assessment, with a particular focus on ultrasonography.
- Published
- 2020
- Full Text
- View/download PDF
3. Noninvasive Diagnosis of Hepatocellular Carcinoma on Sonazoid-Enhanced US: Value of the Kupffer Phase
- Author
-
Hiroshi Takahashi, Katsutoshi Sugimoto, Naohisa Kamiyama, Kentaro Sakamaki, Tatsuya Kakegawa, Takuya Wada, Yusuke Tomita, Masakazu Abe, Yu Yoshimasu, Hirohito Takeuchi, and Takao Itoi
- Subjects
ultrasound ,contrast media ,Sonazoid ,hepatocellular carcinoma ,CEUS ,LI-RADS ,Medicine (General) ,R5-920 - Abstract
The aim of this study was to compare the diagnostic performance of Contrast-Enhanced US Liver Imaging Reporting and Data System (CEUS LI-RADS) version 2017, which includes portal- and late-phase washout as a major imaging feature, with that of modified CEUS LI-RADS, which includes Kupffer-phase findings as a major imaging feature. Participants at risk of hepatocellular carcinoma (HCC) with treatment-naïve hepatic lesions (≥1 cm) were recruited and underwent Sonazoid-enhanced US. Arterial phase hyperenhancement (APHE), washout time, and echogenicity in the Kupffer phase were evaluated using both criteria. The diagnostic performance of both criteria was analyzed using the McNemar test. The evaluation was performed on 102 participants with 102 lesions (HCCs (n = 52), non-HCC malignancies (n = 36), and benign (n = 14)). Among 52 HCCs, non-rim APHE was observed in 92.3% (48 of 52). By 5 min, 73.1% (38 of 52) of HCCs showed mild washout, while by 10 min or in the Kupffer phase, 90.4% (47 of 52) of HCCs showed hypoenhancement. The sensitivity (67.3%; 35 of 52; 95% CI: 52.9%, 79.7%) of modified CEUS LI-RADS criteria was higher than that of CEUS LI-RADS criteria (51.9%; 27 of 52; 95% CI: 37.6%, 66.0%) (p = 0.0047). In conclusion, non-rim APHE with hypoenhancement in the Kupffer phase on Sonazoid-enhanced US is a feasible criterion for diagnosing HCC.
- Published
- 2022
- Full Text
- View/download PDF
4. Usefulness of Modified CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma Using Sonazoid
- Author
-
Katsutoshi Sugimoto, Tatsuya Kakegawa, Hiroshi Takahashi, Yusuke Tomita, Masakazu Abe, Yu Yoshimasu, Hirohito Takeuchi, Yoshitaka Kasai, and Takao Itoi
- Subjects
ultrasound ,contrast media ,Sonazoid ,hepatocellular carcinoma ,CEUS ,LI-RADS ,Medicine (General) ,R5-920 - Abstract
The Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) was introduced for classifying suspected hepatocellular carcinoma (HCC). However, it cannot be applied to Sonazoid. We assessed the diagnostic usefulness of a modified CEUS LI-RADS for HCC and non-HCC malignancies based on sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Patients with chronic liver disease at risk for HCC were evaluated retrospectively. Nodules ≥1 cm with arterial phase hyperenhancement, no early washout (within 60 s), and contrast defects in the Kupffer phase were classified as LR-5. Nodules showing early washout, contrast defects in the Kupffer phase, and/or rim enhancement were classified as LR-M. A total of 104 nodules in 104 patients (median age: 70.0 years; interquartile range: 54.5–78.0 years; 74 men) were evaluated. The 48 (46.2%) LR-5 lesions included 45 HCCs, 2 high-flow hemangiomas, and 1 adrenal rest tumor. The PPV of LR-5 for HCC was 93.8% (95% confidence interval (CI): 82.8–98.7%). The 22 (21.2%) LR-M lesions included 16 non-HCC malignancies and 6 HCCs. The PPV of LR-M for non-HCC malignancies, including six intrahepatic cholangiocarcinomas, was 100% (95% CI: 69.8–100%). In conclusion, in the modified CEUS LI-RADS for Sonazoid, LR-5 and LR-M are good predictors of HCC and non-HCC malignancies, respectively.
- Published
- 2020
- Full Text
- View/download PDF
5. A case of suspected autoimmune encephalitis after the introduction of atezolizumab + bevacizumab therapy for hepatocellular carcinoma
- Author
-
Hiroshi Takahashi, Takao Itoi, Hirohito Takeuchi, Takuya Wada, Yu Yoshimasu, Yusuke Tomita, Hiroo Terashi, Katsutoshi Sugimoto, Tatsuya Kakegawa, Kazuhiro Saito, Taiki Hirata, and Masakazu Abe
- Subjects
Oncology ,Autoimmune encephalitis ,medicine.medical_specialty ,Hepatology ,Bevacizumab ,business.industry ,Atezolizumab ,Hepatocellular carcinoma ,Internal medicine ,Medicine ,business ,medicine.disease ,medicine.drug - Published
- 2021
- Full Text
- View/download PDF
6. Irreversible electroporation of hepatocellular carcinoma: the role of ultrasonography
- Author
-
Takao Itoi, Katsutoshi Sugimoto, Hirohito Takeuchi, Masakazu Abe, Yoshitaka Kasai, and Yu Yoshimasu
- Subjects
medicine.medical_specialty ,lcsh:Medical technology ,Radiofrequency ablation ,medicine.medical_treatment ,Thermal ablation ,Review Article ,ablation ,030218 nuclear medicine & medical imaging ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,irreversible electroporation ,law ,Medicine ,Radiology, Nuclear Medicine and imaging ,business.industry ,fungi ,Microwave ablation ,hepatocellular carcinoma ,ultrasonography ,Irreversible electroporation ,medicine.disease ,Ablation ,lcsh:R855-855.5 ,Early results ,Hepatocellular carcinoma ,030211 gastroenterology & hepatology ,Radiology ,Ultrasonography ,business - Abstract
Irreversible electroporation (IRE) is a novel form of soft tissue ablation therapy that uses high-current electrical pulses to induce the formation of pores in the cell membrane, leading to cell death. Although outcome data for the ablation of hepatocellular carcinoma (HCC) by IRE are limited, early results are encouraging and may suggest equivalency to the outcomes achieved by thermal ablation methods such as radiofrequency ablation (RFA) and microwave ablation (MWA). However, IRE can be a challenging and very time-consuming procedure compared to RFA and MWA. In this review article, we not only evaluate the efficacy and safety of IRE for the treatment of HCC, but also discuss imaging guidance, ablation monitoring, and endpoint assessment, with a particular focus on ultrasonography.
- Published
- 2020
- Full Text
- View/download PDF
7. Noninvasive Diagnosis of Hepatocellular Carcinoma on Sonazoid-Enhanced US: Value of the Kupffer Phase
- Author
-
Hiroshi Takahashi, Katsutoshi Sugimoto, Naohisa Kamiyama, Kentaro Sakamaki, Tatsuya Kakegawa, Takuya Wada, Yusuke Tomita, Masakazu Abe, Yu Yoshimasu, Hirohito Takeuchi, and Takao Itoi
- Subjects
Medicine (General) ,R5-920 ,Sonazoid ,ultrasound ,Clinical Biochemistry ,CEUS ,LI-RADS ,hepatocellular carcinoma ,contrast media ,Article - Abstract
The aim of this study was to compare the diagnostic performance of Contrast-Enhanced US Liver Imaging Reporting and Data System (CEUS LI-RADS) version 2017, which includes portal- and late-phase washout as a major imaging feature, with that of modified CEUS LI-RADS, which includes Kupffer-phase findings as a major imaging feature. Participants at risk of hepatocellular carcinoma (HCC) with treatment-naïve hepatic lesions (≥1 cm) were recruited and underwent Sonazoid-enhanced US. Arterial phase hyperenhancement (APHE), washout time, and echogenicity in the Kupffer phase were evaluated using both criteria. The diagnostic performance of both criteria was analyzed using the McNemar test. The evaluation was performed on 102 participants with 102 lesions (HCCs (n = 52), non-HCC malignancies (n = 36), and benign (n = 14)). Among 52 HCCs, non-rim APHE was observed in 92.3% (48 of 52). By 5 min, 73.1% (38 of 52) of HCCs showed mild washout, while by 10 min or in the Kupffer phase, 90.4% (47 of 52) of HCCs showed hypoenhancement. The sensitivity (67.3%; 35 of 52; 95% CI: 52.9%, 79.7%) of modified CEUS LI-RADS criteria was higher than that of CEUS LI-RADS criteria (51.9%; 27 of 52; 95% CI: 37.6%, 66.0%) (p = 0.0047). In conclusion, non-rim APHE with hypoenhancement in the Kupffer phase on Sonazoid-enhanced US is a feasible criterion for diagnosing HCC.
- Published
- 2021
8. Comparisons of Radiofrequency Ablation, Microwave Ablation, and Irreversible Electroporation by Using Propensity Score Analysis for Early Stage Hepatocellular Carcinoma
- Author
-
Takuya Wada, Katsutoshi Sugimoto, Kentaro Sakamaki, Hiroshi Takahashi, Tatsuya Kakegawa, Yusuke Tomita, Masakazu Abe, Yu Yoshimasu, Hirohito Takeuchi, and Takao Itoi
- Subjects
Cancer Research ,Oncology ,irreversible electroporation ,microwave ablation ,hepatocellular carcinoma ,radiofrequency ablation - Abstract
Background: Despite the diversity of thermal ablations, such as radiofrequency ablation (RFA) and microwave ablation (MWA), and non-thermal ablation, such as irreversible electroporation (IRE) cross-comparisons of multiple ablative modalities for hepatocellular carcinoma (HCC) treatment remain scarce. Thus, we investigated the therapeutic outcomes of different three ablation modalities in the treatment of early stage HCC. Methods: A total of 322 consecutive patients with 366 HCCs (mean tumor size ± standard deviation: 1.7 ± 0.9 cm) who underwent RFA (n = 216, 59.0%), MWA (n = 91, 28.3%), or IRE (n = 15, 4.7%) were included. Local tumor progression (LTP) rates for LTP were compared among the three modalities. Propensity score-matched analysis was used to reduce selection bias. Results: A significant difference in 2-year LTP rates between the IRE and RFA groups (IRE, 0.0% vs. RFA, 45.0%; p = 0.005) was found. There was no significant difference in 2-year LTP rates between the IRE and MWA groups (IRE, 0.0% vs. MWA, 25.0%; p = 0.103) as well as between the RFA and MWA groups (RFA, 18.2% vs. MWA, 20.6%; p = 0.586). Conclusion: IRE provides better local tumor control than RFA as a first-line therapeutic option for small perivascular HCC.
- Published
- 2023
- Full Text
- View/download PDF
9. Washout-Parametric Imaging with Sonazoid for Enhanced Differentiation of Focal Liver Lesions.
- Author
-
Yutaro Nakano, Tatsuya Kakegawa, Katsutoshi Sugimoto, Shunsuke Nakamura, Keisuke Nakajima, Mayuka Masuda, Hiroshi Takahashi, Takuya Wada, Hirohito Takeuchi, and Takao Itoi
- Subjects
RECEIVER operating characteristic curves ,CONTRAST-enhanced ultrasound ,INTRACLASS correlation ,HEPATOCELLULAR carcinoma ,DIFFERENTIAL diagnosis - Abstract
Background/Aims This study aimed to compare the diagnostic performance of washout-parametric imaging (WOPI) with conventional contrast-enhanced ultrasound (cCEUS) in the differential diagnosis of focal liver lesions (FLLs) including Hepatocellular Carcinoma. Methods A total of 181 FLLs were imaged with CEUS using Sonazoid and recorded for up to 10 minutes in a prospective setting. The WOPI was constructed by using three images: arterial phase (peak enhancement), early portal venous phase (1-minute post injection), and vasculo-Kupffer phase (5- or 10-minutes post injection) images. The intensity variation of these images was color-coded and superimposed into one image providing a visual representation of washout timing across the lesions. Among the 181 FLLs, 30 hepatocellular carcinoma (HCC), 30 non-HCC malignancies, and 30 benign lesions were randomly selected for an observer study. Both techniques (cCEUS and WOPI) were assessed by four off-site readers who classified each lesion as benign or malignant using a continuous rating scale where the left and right ends corresponded to definitely benign and definitely malignant, respectively. The area under the receiver operating characteristic curve (AUC) for both techniques (cCEUS and WOPI: Delong test) and interobserver agreements (intraclass correlation coefficient: ICC) were evaluated. Results The difference in average AUC values of WOPI and cCEUS was 0.0062 (95% confidence interval [CI]: 0.0285, -0.0161), including no difference between the two techniques. Interobserver agreement was higher with WOPI compared with cCEUS, with an increase ICC from 0.67 to 0.77. Conclusion The diagnostic performance of WOPI is comparable to that of cCEUS in differentiating FLLs, with improved interobserver agreements. [ABSTRACT FROM AUTHOR]
- Published
- 2024
10. Predictive Factors for Hepatocellular Carcinoma Occurrence or Recurrence after Direct-Acting Antiviral Agents in Patients with Chronic Hepatitis C
- Author
-
Takao Itoi, Ikuo Nakamura, Yoshihiro Furuichi, Hirohito Takeuchi, Yoshitaka Kasai, Yu Yoshimasu, and Katsutoshi Sugimoto
- Subjects
Adult ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Time Factors ,Antiviral Agents ,Risk Assessment ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Recurrence ,Risk Factors ,Internal medicine ,Carcinoma ,medicine ,Humans ,Blood test ,Cumulative incidence ,Tokyo ,neoplasms ,Aged ,Retrospective Studies ,Aged, 80 and over ,Univariate analysis ,medicine.diagnostic_test ,business.industry ,Incidence ,Incidence (epidemiology) ,Liver Neoplasms ,Retrospective cohort study ,Hepatitis C ,Hepatitis C, Chronic ,Middle Aged ,Protective Factors ,medicine.disease ,digestive system diseases ,Treatment Outcome ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Female ,030211 gastroenterology & hepatology ,alpha-Fetoproteins ,business - Abstract
Background & Aims: Direct-acting antiviral agents (DAAs) and the risk of hepatocellular carcinoma (HCC) is controversially reported in the literature. The primary endpoints of this study were to clarify the cumulative incidence and recurrence rate of HCC after DAA treatment. The secondary endpoints were to identify the factors associated with the occurrence or recurrence of HCC after DAAs treatment.Methods: Of 234 HCV patients, 211 with no history of HCC (no-HCC-history group) and 23 with previous treated HCC history (HCC-history group) were treated with DAAs and followed for more than 24 weeks to determine the incidence of HCC. Platelet count, albumin, α-fetoprotein (AFP) level, L3%, the FIB-4 index and APRI scores were analyzed as possible factors associated with HCC occurrence and recurrence. An intergroup comparison was made of the cumulative incidence of HCC. Cox proportional hazards regression was used to determine associations between blood test values and risk of HCC.Results: The median observation period was 21 months. Cumulative incidence of HCC was higher in the HCChistory group than in the no-HCC-history group (p < 0.0001, 19.0 and 0.52 per 100 patient-years, respectively). Univariate analysis revealed platelet count, albumin, α-fetoprotein (AFP) level, AFP-L3%, and FIB-4 index and APRI scores at the end of DAA treatment as being significantly associated with occurrence/recurrence of HCC. Multivariate analysis revealed that AFP levels before and after the administration of DAAs and AFP-L3% after DAA were independently associated with the occurrence/recurrence of HCC (p = 0.045, 0.043, 0.005, respectively).Conclusion: The HCC occurrence rate after DAA treatment was very low, and the recurrence rate lower than that in previous interferon reports. The AFP level and AFP-L3% were identified as important factors in predicting occurrence/recurrence of HCC. Careful observation is needed when increased levels of AFP or AFP-L3% after DAAs treatment are observed.
- Published
- 2019
- Full Text
- View/download PDF
11. Usefulness of Modified CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma Using Sonazoid
- Author
-
Tatsuya Kakegawa, Yoshitaka Kasai, Masakazu Abe, Yusuke Tomita, Hiroshi Takahashi, Katsutoshi Sugimoto, Hirohito Takeuchi, Yu Yoshimasu, and Takao Itoi
- Subjects
medicine.medical_specialty ,Adrenal Rest Tumor ,Sonazoid ,Clinical Biochemistry ,Chronic liver disease ,contrast media ,Article ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Text mining ,Interquartile range ,medicine ,neoplasms ,lcsh:R5-920 ,business.industry ,ultrasound ,Ultrasound ,hepatocellular carcinoma ,medicine.disease ,Confidence interval ,digestive system diseases ,Rim enhancement ,Hepatocellular carcinoma ,CEUS ,LI-RADS ,030211 gastroenterology & hepatology ,Radiology ,business ,lcsh:Medicine (General) - Abstract
The Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) was introduced for classifying suspected hepatocellular carcinoma (HCC). However, it cannot be applied to Sonazoid. We assessed the diagnostic usefulness of a modified CEUS LI-RADS for HCC and non-HCC malignancies based on sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Patients with chronic liver disease at risk for HCC were evaluated retrospectively. Nodules ≥1 cm with arterial phase hyperenhancement, no early washout (within 60 s), and contrast defects in the Kupffer phase were classified as LR-5. Nodules showing early washout, contrast defects in the Kupffer phase, and/or rim enhancement were classified as LR-M. A total of 104 nodules in 104 patients (median age: 70.0 years; interquartile range: 54.5–78.0 years; 74 men) were evaluated. The 48 (46.2%) LR-5 lesions included 45 HCCs, 2 high-flow hemangiomas, and 1 adrenal rest tumor. The PPV of LR-5 for HCC was 93.8% (95% confidence interval (CI): 82.8–98.7%). The 22 (21.2%) LR-M lesions included 16 non-HCC malignancies and 6 HCCs. The PPV of LR-M for non-HCC malignancies, including six intrahepatic cholangiocarcinomas, was 100% (95% CI: 69.8–100%). In conclusion, in the modified CEUS LI-RADS for Sonazoid, LR-5 and LR-M are good predictors of HCC and non-HCC malignancies, respectively.
- Published
- 2020
12. Adrenocortical Scintigraphy With SPECT/CT for the Diagnosis of Hepatic Adrenal Rest
- Author
-
Katsutoshi Sugimoto, Hirohito Takeuchi, Mana Yoshimura, Masako Kawasaki, and Kazuhiro Saito
- Subjects
Adult ,Pathology ,medicine.medical_specialty ,Angiomyolipoma ,Single Photon Emission Computed Tomography Computed Tomography ,Choristoma ,Scintigraphy ,030218 nuclear medicine & medical imaging ,Diagnosis, Differential ,03 medical and health sciences ,0302 clinical medicine ,Adrenal Glands ,medicine ,Carcinoma ,Humans ,Radiology, Nuclear Medicine and imaging ,medicine.diagnostic_test ,business.industry ,Liver Neoplasms ,Adrenal rest ,General Medicine ,Hyperplasia ,Hepatocellular adenoma ,Middle Aged ,medicine.disease ,Posterior segment of eyeball ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Female ,business - Abstract
Hepatic adrenal rest include ectopic adrenal tissue in the liver and adrenohepatic fusion. Long-lasting hyperstimulation of that tissue induces hyperplasia sometimes simulating true tumors. True autonomic tumors originating from ectopic adrenal tissue with or without hyperfunction are rare. Hepatic adrenal rest sometimes has similar imaging findings to lipid-rich hepatocellular carcinoma or angiomyolipoma, containing obvious lipid component. But in our cases, tumors showed hypervascular patterns similar to hepatocellular adenoma or carcinoma. Therefore, adrenocortical scintigraphy with SPECT/CT should be taken into consideration to diagnose tumoral lesions in the posterior segment of the right hepatic lobe with or without an obvious lipid component.
- Published
- 2019
13. Irreversible Electroporation versus Radiofrequency Ablation: Comparison of Systemic Immune Responses in Patients with Hepatocellular Carcinoma
- Author
-
Fuminori Moriyasu, Kentaro Sakamaki, Hirohito Takeuchi, Katsutoshi Sugimoto, Kazuhiro Kakimi, Nao Fujieda, Kazuhiro Saito, Eiichi Sato, and Takao Itoi
- Subjects
Ablation Techniques ,Male ,Pathology ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Time Factors ,Radiofrequency ablation ,medicine.medical_treatment ,030218 nuclear medicine & medical imaging ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,law ,medicine ,Carcinoma ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,Macrophage Migration-Inhibitory Factors ,Aged ,Aged, 80 and over ,Radiofrequency Ablation ,business.industry ,Electroporation ,fungi ,Liver Neoplasms ,Irreversible electroporation ,Ablation ,medicine.disease ,Tumor Burden ,Intramolecular Oxidoreductases ,Treatment Outcome ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Macrophage migration inhibitory factor ,Female ,Cardiology and Cardiovascular Medicine ,business ,Ablation zone - Abstract
Purpose Irreversible electroporation (IRE) differs from thermal radiofrequency (RF) ablation, especially in terms of the reparative process in the ablation zone induced. To elucidate this, the systemic immune responses after 2 mechanistically different types of ablation (IRE and RF ablation) were evaluated in patients with hepatocellular carcinoma (HCC). Materials and Methods Twenty-one patients with HCC who underwent either RF ablation (n = 11) or IRE (n = 10) were studied. Peripheral blood samples were collected from all patients at 4 timepoints: before ablation, within 1 hour after ablation, 1 day after ablation, and 4 days after ablation. The phenotypes and functions of immune cells in peripheral blood and serum levels of cytokines and chemokines were monitored and analyzed using the mixed-effects model. Follow-up radiological images were also obtained to assess temporal changes in the ablation zone. Results The most significant difference was seen in the levels of macrophage migration inhibitory factor (MIF) in the IRE group compared to the RF ablation group (P = .0011): the serum levels of MIF in the IRE group significantly increased immediately after IRE and then rapidly decreased to the pre-ablation range 1 day after IRE, but, in contrast, no consistent trend was observed in the RF ablation group. The axial diameter (P = .0009) and area (P = .0192) of the ablation zone of IRE were significantly smaller than those of RF ablation 1 year after ablation. Conclusions IRE was found to be associated with a significant early increase in MIF levels, which may facilitate the early reparative process and result in significant shrinkage of the ablation zone.
- Published
- 2018
14. Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan
- Author
-
Takatomo Sano, Fuminori Moriyasu, Kazuhiro Saito, Ikuo Nakamura, Yoshihiro Furuichi, Mayumi Ando, Hirohito Takeuchi, Yoshiyuki Kobayashi, Saori Ogawa, Katsutoshi Sugimoto, and Toshifumi Mori
- Subjects
Ablation Techniques ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Percutaneous ,medicine.medical_treatment ,Anesthesia, General ,Lesion ,Japan ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,Adverse effect ,Aged ,Neoplasm Staging ,Ultrasonography ,business.industry ,Liver Neoplasms ,Ultrasound ,Perflubutane Microbubble ,Irreversible electroporation ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Surgery ,Radiation therapy ,Electroporation ,Treatment Outcome ,Hepatocellular carcinoma ,Female ,Radiology ,medicine.symptom ,Tomography, X-Ray Computed ,business ,Follow-Up Studies - Abstract
This clinical study was conducted to evaluate the safety and short-term outcomes of irreversible electroporation (IRE) for the treatment of patients with hepatocellular carcinoma (HCC) in Japan. The study was designed in a prospective setting. Five patients (3 men and 2 women; mean age, 66.6 ± 5.8 years) with 6 HCCs were enrolled and treated using percutaneous ultrasound (US)-guided IRE. Safety was assessed based on adverse events and laboratory values. Local control was assessed using contrast-enhanced US with a perflubutane microbubble contrast agent, contrast-enhanced multiphase CT, and gadoxetic acid-enhanced MRI (EOB-MRI) at designated points. The tumors ranged in diameter from 11 to 28 mm (mean diameter, 17.5 ± 6.3 mm). Five of the 6 tumors (83 %) were successfully treated, with no local recurrence to date (mean follow-up 244 ± 55 days). In 1 lesion located in liver segment 1, residual tumor was diagnosed at 7 days after intervention by follow-up EOB-MRI. No serious complications related to the IRE procedure were observed. The results of this study suggest that image-guided percutaneous IRE can achieve satisfactory local disease control, particularly for small HCCs, and is well tolerated by patients.
- Published
- 2015
- Full Text
- View/download PDF
15. Mo1448 – Macrophage Migration Inhibitory Factors (MIF) Facilitates Scarless Tissue Regeneration Following Ablation with Irreversible Electroporation in Patients with Hepatocellular Carcinoma
- Author
-
Takao Itoi, Katsutoshi Sugimoto, and Hirohito Takeuchi
- Subjects
Hepatology ,Chemistry ,medicine.medical_treatment ,Hepatocellular carcinoma ,Gastroenterology ,medicine ,Cancer research ,Macrophage migration inhibitory factor ,In patient ,Irreversible electroporation ,Ablation ,medicine.disease - Published
- 2019
- Full Text
- View/download PDF
16. Predictive Factors for Hepatocellular Carcinoma Occurrence or Recurrence after Direct-Acting Antiviral Agents in Patients with Chronic Hepatitis C.
- Author
-
Yu Yoshimasu, Yoshihiro Furuichi, Yoshitaka Kasai, Hirohito Takeuchi, Katsutoshi Sugimoto, Ikuo Nakamura, and Takao Itoi
- Subjects
- *
HEPATOCELLULAR carcinoma , *ANTIVIRAL agents - Abstract
Background & Aims: Direct-acting antiviral agents (DAAs) and the risk of hepatocellular carcinoma (HCC) is controversially reported in the literature. The primary endpoints of this study were to clarify the cumulative incidence and recurrence rate of HCC after DAA treatment. The secondary endpoints were to identify the factors associated with the occurrence or recurrence of HCC after DAAs treatment. Methods: Of 234 HCV patients, 211 with no history of HCC (no-HCC-history group) and 23 with previous treated HCC history (HCC-history group) were treated with DAAs and followed for more than 24 weeks to determine the incidence of HCC. Platelet count, albumin, a-fetoprotein (AFP) level, L3%, the FIB-4 index and APRI scores were analyzed as possible factors associated with HCC occurrence and recurrence. An intergroup comparison was made of the cumulative incidence of HCC. Cox proportional hazards regression was used to determine associations between blood test values and risk of HCC. Results: The median observation period was 21 months. Cumulative incidence of HCC was higher in the HCChistory group than in the no-HCC-history group (p < 0.0001, 19.0 and 0.52 per 100 patient-years, respectively). Univariate analysis revealed platelet count, albumin, a-fetoprotein (AFP) level, AFP-L3%, and FIB-4 index and APRI scores at the end of DAA treatment as being significantly associated with occurrence/recurrence of HCC. Multivariate analysis revealed that AFP levels before and after the administration of DAAs and AFP-L3% after DAA were independently associated with the occurrence/recurrence of HCC (p = 0.045, 0.043, 0.005, respectively). Conclusion: The HCC occurrence rate after DAA treatment was very low, and the recurrence rate lower than that in previous interferon reports. The AFP level and AFP-L3% were identified as important factors in predicting occurrence/recurrence of HCC. Careful observation is needed when increased levels of AFP or AFP-L3% after DAAs treatment are observed. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.